1.85  -0.1 (-5.13%)		05-23 16:00
Open: 1.98 High: 2.016 Volume: 305,441		Pre. Close: 1.95 Low: 1.8 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	2.35	1-year :	2.75
Resists	First :	2.01	Second :	2.35
Pivot price	1.7
Supports	First :	1.62	Second :	1.37
MAs	MA(5) :	1.79	MA(20) :	1.65
	MA(100) :	1.76	MA(250) :	3.97
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	78.6	D(3) :	80.9
RSI	RSI(14): 64.3
52-week	High :	18.39	Low :	1.29

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NLSP ] has closed below upper band by 8.7%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.02 - 2.03	2.03 - 2.04
Low:	1.78 - 1.79	1.79 - 1.8
Close:	1.84 - 1.85	1.85 - 1.86

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Wed, 21 May 2025
NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com

Tue, 15 Apr 2025
NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks

Mon, 31 Mar 2025
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - Yahoo Finance

Fri, 31 Jan 2025
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga

Fri, 31 Jan 2025
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - marketscreener.com

Mon, 27 Jan 2025
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - ACCESS Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	0 (M)
Held by Insiders	33.5 (%)
Held by Institutions	17.3 (%)
Shares Short	91 (K)
Shares Short P.Month	34 (K)

EPS	-6.74
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-9.4
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-227.8 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.56
Qtrly Earnings Growth	0 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-0.28
PEG Ratio	0
Price to Book value	-0.2
Price to Sales	0
Price to Cash Flow	-1.92

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.